63 results about "Nucleotide Aptamers" patented technology

The invention discloses a micro-molecular nucleotide adaptor medicament for hepatitis C virus and application thereof. The DNA adaptor sequence is the nucleotide sequence represented by SEQ IN No. 1-29. The method comprises the following steps: firstly, building a random single-chain DNA library; secondly, synthesizing a double-chain DNA library; thirdly, SELEX selecting; fourthly, PCR amplifying; fifthly, cloning and detecting sequence; and sixthly, testing DNA adaptor efficiency by level tests on cells in vitro. The micro-molecular nucleotide adaptor is applied to preparing medicaments in treating hepatitis C virus and preventing hepatitis C virus infecting human cells. The DNA adaptor can be directly used as agonist and diagnostic reagent of hepatitis C virus, can be used for preventing, detecting and treating hepatitis C virus, and overcomes the defects that combined treatment with alpha interferon and ribavirin has strong side effect when alpha interferon or antivirus medicaments such as alpha interferon, ribavirin and the like which are combined are used for treating hepatitis C virus in clinic, and that hepatitis C virus has no vaccine to prevent currently.

The invention discloses an oligonucleotide aptamer set (Sp15, Sp16) for specifically identifying Bacillus cereus, belonging to the fields of food sanitation and clinical medicine detection. In order to overcome the defect of no Bacillus cereus nucleotide aptamer in the prior art, a competitive Cell-SELEX technique is utilized to perform screening, amplification, enzyme digestion, sequencing and affinity and specificity analysis on the in-vitro synthetic random single-chain oligonucleotide library by using a complete active Bacillus cereus cell as the target, thereby obtaining the oligonucleotide aptamer set for specifically identifying Bacillus cereus. The screened aptamers have the characteristics of high affinity, high specificity, stable properties, low cost and the like, are convenient for in-vitro synthesis, can be used for detecting Bacillus cereus in the food and environment by marking the functional group or fluorescent dye, and provide a new option for the antibody-dependent detection method at present.

The invention discloses a Non-Equilibrium Capillary Electrophoresis of Equilibrium Mixtures (NECEEM) method and NECEEM-based practical applications. The NECEEM method is a homogeneous technique, which, in contrast to heterogeneous methods, does not require affixing molecules to a solid substrate. The method of the invention facilitates 3 practical applications. In the first application, the method allows the finding of kinetic and thermodynamic parameters of complex formation. It advantageously allows for revealing two parameters, the equilibrium dissociation constant, Kd, and the monomolecular rate constant of complex decay, koff, in a single experiment. In the second practical application, the method of this invention provides an approach for quantitative affinity analysis of target molecules. It advantageously allows for the use of affinity probes with relatively high values of koff. In the third practical application, the method of this invention presents a new and powerful approach to select target-binding molecules (ligands) from complex mixtures. Unique capabilities of the method in its third application include but not limited to: (a) the selection of ligands with pre-determined ranges of kinetic and thermodynamic parameters of target-ligand interactions, (b) the selection of ligands present in minute amounts in complex mixtures of biological or synthetic compounds such as combinatorial libraries of oligonucleotides, and (c) the selection of ligands for targets available in very low amounts. In particular, the method of this invention provides a novel approach for the selection of oligonucleotide aptamers. The NECEEM-based method can be used for discovery and characterization of drug candidates and the development of new diagnostic methods.